Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 17

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 17
---
ategic relationship or grant, management anticipates that our cash resources are sufficient to continue operations through April 2025.
Our future is dependent upon the ability to obtain financing and upon future profitable operations from the development of new business
opportunities. There can be no assurance that we will be successful in accomplishing these objectives. Without such additional capital,
we may be required to curtail or cease operations and be required to realize our assets and discharge our liabilities other than in the
normal course of business which could cause investors to suffer the loss of all or a substantial portion of their investment. WithumSmith+Brown,
PC, our independent registered public accounting firm for the fiscal year ended December 31, 2024, has included an explanatory paragraph
in its opinion that accompanies our audited consolidated financial statements as of and for the year ended December 31, 2024, indicating
that our current liquidity position raises substantial doubt about our ability to continue as a going concern.

We have a limited operating history, which makes it difficult to evaluate our current business and future prospects.

We are a company with limited operating history, and
our operations are subject to all of the risks inherent in establishing a new business enterprise. The likelihood of our success must
be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the
formation of a new business, the development of new technologies or those subject to clinical testing, and the competitive and regulatory
environment in which we will operate. To date, we have generated revenue from a limited market launch of CyPath Lung in
Texas. There can be no assurance that we will be able to successfully expand our commercialization efforts or that we will obtain the
necessary regulatory approvals that will allow us to expand our marketing efforts. We may not be able to maintain certification of CyPath
Lung as an LDT in accordance with CAP/CLIA guidance and regulations, or obtain approval of our diagnostic tests in development by the
CMS, the FDA, European Medicines Agency, or Chinese National Medical Products Administration. Even if we do so and are also able to commercialize
our diagnostic tests, we may never generate revenue sufficient to become profitable. Our failure to generate revenue and profit would
likely cause our securities to decrease in value or become worthless.

In addition, while we anticipate generating continued
revenue from PPLS, our CAP-accredited, CLIA-certified clinical pathology laboratory, we do not expect to immediately derive profit from
revenue from P